Edgewise Therapeutics
EWTX
129 hedge funds and large institutions have $1.67B invested in Edgewise Therapeutics in 2024 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 60 increasing their positions, 28 reducing their positions, and 19 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 28
92% more capital invested
Capital invested by funds: $871M → $1.67B (+$800M)
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
51% more call options, than puts
Call options by funds: $408K | Put options by funds: $270K
12.87% more ownership
Funds ownership: 85.54% → 98.41% (+13%)
11% more funds holding
Funds holding: 116 → 129 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$142M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$43.3M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$38.9M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$36.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$66.4M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$44.8M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$35.6M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$27.8M |
| 5 |
DM
Deerfield Management
New York
|
-$16.8M |
EWTX Hedge Fund Activity: Q1 2024 in Review
129 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q1 2024, worth a combined $1.67B — up 92% from $871M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new EWTX positions and 19 closed out — a net gain of 13 holders — while 60 added to existing stakes and 28 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $142M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $66.4M sold.
- 129 institutional investors held Edgewise Therapeutics (EWTX) as of Q1 2024, up from 116 in Q4 2023.
- Funds reported $1.67B of Edgewise Therapeutics stock for Q1 2024, up 92% quarter-over-quarter.
- 32 funds opened new Edgewise Therapeutics positions in Q1 2024 and 19 closed out, a net change of +13 holders.
- The largest Edgewise Therapeutics buyer in Q1 2024 was RA Capital Management, an estimated $142M added.
- The largest Edgewise Therapeutics seller in Q1 2024 was Novo Holdings A/S, an estimated $66.4M sold.
Based on aggregated 13F filings for Q1 2024.